Conditionnement : 100mg
Synonyms: ABR-215050
| Description | Tasquinimod (ABR-215050) is an oral antiangiogenic agent with potential antitumor activity. It is also an S100A9 inhibitor and binds to the HDAC4Zn2+ binding structural domain with Kd values between 10 and 30 nM. |
| Targets & IC50 | HUVECs:0.500 μM, AhR:1 mM (EC50), HDAC4:10-30 nM (Kd) |
| In vitro | Method: Human MM cells (multiple myeloma cells) were treated with increasing concentrations of Tasquinimod (ABR-215050) (10,25 μM) for 24 h, 48 h, 72 h, and 120 h. The effect of Tasquinimod on the value added of human MM cells was observed. Result Tasquinimod inhibited the growth and proliferation of MM cells in vitro. [1] Method: SKOV3 and SKOV3/DDP cells were treated with 40 μM tasquinimod, and the expression of histone deacetylase 4 (HDAC4), Nur77, Bcl-2 (BH3 structural domain specific), and caspase-3 were analyzed by Western blot and quantitative real-time polymerase chain reaction (qPCR). Result Cell migration and HDAC4 expression levels were significantly reduced, while Nur77 expression levels were elevated. [2] |
| In vivo | Method: Mice were treated with Tasquinimod (ABR-215050) (30 mg/kg), added to the daily drinking water at an early stage after MM cell inoculation, and immune cell populations were studied using flow cytometry. Result Short-term Tasquinimod treatment did not lead to alterations in MM cell homing to the bone marrow, but a significant increase in the total percentage of CD11b cells could be observed, whereas a slight decrease in monocytes and immature myeloid populations (CD11b, Ly6G, Ly6C+-low) was observed, and an increase in macrophage populations (CD11b, F4/80), which showed a more pro-inflammatory phenotype of M1 (MHCII) and the M2 marker CD206.[1] Method: SKOV3 or SKOV3/DDP cells were injected into 4-week-old female BALB/c nude mice. Then, 50 mg/kg Tasquinimod was administered every 3 days. finally, changes in tumor diameter and weight were measured, and apoptosis, migration rate, and related expression of Nur77 and Bcl-2 (BH3 structural domain specific) were detected by flow cytometry, scratch assay, and immunofluorescence. Result Tasquinimod significantly reduced tumor diameter, tumor mass, and in vivo HDAC4 levels in mice. Meanwhile, Nur77 and Bcl-2 (BH3 structural domain specific) levels were elevated. [2] |
| Synonyms | ABR-215050 |
| Cell Research | Tasquinimod is dissolved in DMSO and stored, and then diluted with appropriate media before use[3]. Two human prostate cancer cell lines, CWR-22RH and LNCaP (ATCC) are both androgen independent, but remain sensitive to androgen stimulation of growth, express PSA and a mutated androgen receptor. The hormone independent cell lines LNCaP19 and DU145 are also tested for TSP1 induction after in vitro exposure to Tasquinimod (0.1-100 μM). CWR-22RH, LNCaP and DU145 are grown in RPMI Medium 1640 containing 10% FCS and L-Glutamine mixture, while LNCAP19 is cultured in RPMI-medium with 10% hormone free (RDCC) FCS[3]. |
| Molecular Weight | 406.36 |
| Formula | C20H17F3N2O4 |
| Cas No. | 254964-60-8 |
| Smiles | O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2OC)N(C)C3=CC=C(C(F)(F)F)C=C3 |
| Relative Density. | 1.427 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 9.00 mg/mL (22.15 mM), Sonication is recommended. DMSO: 65.00 mg/mL (159.96 mM), Sonication is recommended.  H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.29 mg/mL (17.94 mM), Solution. 10% DMSO+90% Saline: < 7.29 mg/mL (17.94 mM), insoluble. Lower concentrations may be soluble, but exact solubility limit is unknown. 2% DMSO+40% PEG300+5% Tween-80+53% Saline: 1.00 mg/mL (2.46 mM) Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
